.jpg)
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analysts
Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine patients dosed so far.
Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine patients dosed so far.
